An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England (OBSERVA) First published 13/11/2012 Last updated 02/07/2024 EU PAS number:EUPAS3136 Study Finalised